{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:08:28Z","timestamp":1792782508973,"version":"4.5.0"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Helsinki","id":[{"id":"https:\/\/ror.org\/040af2s02","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00125-026-06816-0","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:15:38Z","timestamp":1786029338000},"page":"3048-3072","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Screening and diagnosis of liver disease in diabetes: a guide and evidence-based assessment"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9313-9324","authenticated-orcid":false,"given":"Sami F.","family":"Qadri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"issue":"3","key":"6816_CR1","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","volume":"78","author":"V Ajmera","year":"2023","unstructured":"Ajmera V, Cepin S, Tesfai K et al (2023) A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol 78(3):471\u2013478. https:\/\/doi.org\/10.1016\/j.jhep.2022.11.010","journal-title":"J Hepatol"},{"key":"6816_CR2","doi-asserted-by":"publisher","unstructured":"Younossi ZM, Golabi P, Price JK et al (2024) The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol 22(10):1999\u20132010.e1998. https:\/\/doi.org\/10.1016\/j.cgh.2024.03.006","DOI":"10.1016\/j.cgh.2024.03.006"},{"issue":"6","key":"6816_CR3","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V et al (2023) A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 79(6):1542\u20131556. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"6816_CR4","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.2337\/dc26-S004","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes (2026) 4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes-2026. Diabetes Care 49(Suppl 1):S61\u2013S88. https:\/\/doi.org\/10.2337\/dc26-S004","journal-title":"Diabetes Care"},{"issue":"10","key":"6816_CR5","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","volume":"9","author":"H Hagstrom","year":"2024","unstructured":"Hagstrom H, Shang Y, Hegmar H, Nasr P (2024) Natural history and progression of metabolic dysfunction-associated steatotic liver disease. Lancet Gastroenterol Hepatol 9(10):944\u2013956. https:\/\/doi.org\/10.1016\/S2468-1253(24)00193-6","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"6816_CR6","doi-asserted-by":"publisher","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L et al (2015) Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149(2):367\u2013378 e365; quiz e314\u2013365. https:\/\/doi.org\/10.1053\/j.gastro.2015.04.005","DOI":"10.1053\/j.gastro.2015.04.005"},{"issue":"21","key":"6816_CR7","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I et al (2025) Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med 392(21):2089\u20132099. https:\/\/doi.org\/10.1056\/NEJMoa2413258","journal-title":"N Engl J Med"},{"issue":"6","key":"6816_CR8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD et al (2024) A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med 390(6):497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000","journal-title":"N Engl J Med"},{"issue":"4","key":"6816_CR9","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","volume":"159","author":"G Lassailly","year":"2020","unstructured":"Lassailly G, Caiazzo R, Ntandja-Wandji LC et al (2020) Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology 159(4):1290\u20131301. https:\/\/doi.org\/10.1053\/j.gastro.2020.06.006","journal-title":"Gastroenterology"},{"issue":"3","key":"6816_CR10","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity","year":"2024","unstructured":"European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity (2024) EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 81(3):492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031","journal-title":"J Hepatol"},{"issue":"5","key":"6816_CR11","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS et al (2023) AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77(5):1797\u20131835. https:\/\/doi.org\/10.1097\/HEP.0000000000000323","journal-title":"Hepatology"},{"issue":"2","key":"6816_CR12","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1148\/radiol.2021204288","volume":"301","author":"J Starekova","year":"2021","unstructured":"Starekova J, Hernando D, Pickhardt PJ, Reeder SB (2021) Quantification of liver fat content with CT and MRI: state of the art. Radiology 301(2):250\u2013262. https:\/\/doi.org\/10.1148\/radiol.2021204288","journal-title":"Radiology"},{"issue":"1","key":"6816_CR13","doi-asserted-by":"publisher","first-page":"100928","DOI":"10.1016\/j.jhepr.2023.100928","volume":"6","author":"S Qadri","year":"2024","unstructured":"Qadri S, Vartiainen E, Lahelma M et al (2024) Marked difference in liver fat measured by histology vs. magnetic resonance-proton density fat fraction: a meta-analysis. JHEP Rep 6(1):100928. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100928","journal-title":"JHEP Rep"},{"issue":"4","key":"6816_CR14","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1002\/hep.29639","volume":"67","author":"C Caussy","year":"2018","unstructured":"Caussy C, Alquiraish MH, Nguyen P et al (2018) Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. Hepatology 67(4):1348\u20131359. https:\/\/doi.org\/10.1002\/hep.29639","journal-title":"Hepatology"},{"issue":"5","key":"6816_CR15","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/hep.25889","volume":"56","author":"P Bedossa","year":"2012","unstructured":"Bedossa P, Poitou C, Veyrie N et al (2012) Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 56(5):1751\u20131759. https:\/\/doi.org\/10.1002\/hep.25889","journal-title":"Hepatology"},{"issue":"16","key":"6816_CR16","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"KGMM Alberti","year":"2009","unstructured":"Alberti KGMM, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16):1640\u20131645. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.192644","journal-title":"Circulation"},{"issue":"6","key":"6816_CR17","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jhep.2024.06.036","volume":"81","author":"D Marti-Aguado","year":"2024","unstructured":"Marti-Aguado D, Calleja JL, Vilar-Gomez E et al (2024) Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease. J Hepatol 81(6):930\u2013940. https:\/\/doi.org\/10.1016\/j.jhep.2024.06.036","journal-title":"J Hepatol"},{"issue":"5","key":"6816_CR18","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.cgh.2024.01.006","volume":"22","author":"P Nasr","year":"2024","unstructured":"Nasr P, Wester A, Ekstedt M et al (2024) Misclassified alcohol-related liver disease is common in presumed metabolic dysfunction-associated steatotic liver disease and highly increases risk for future cirrhosis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 22(5):1048-1057 e1042. https:\/\/doi.org\/10.1016\/j.cgh.2024.01.006","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"11","key":"6816_CR19","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1111\/jgh.16726","volume":"39","author":"MB Aboona","year":"2024","unstructured":"Aboona MB, Danpanichkul P, Chen VL et al (2024) Mortality outcomes in individuals with MASLD versus MASLD and increased alcohol intake. J Gastroenterol Hepatol 39(11):2456\u20132463. https:\/\/doi.org\/10.1111\/jgh.16726","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"6816_CR20","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1002\/hep.29631","volume":"67","author":"F Aberg","year":"2018","unstructured":"Aberg F, Helenius-Hietala J, Puukka P, Farkkila M, Jula A (2018) Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population. Hepatology 67(6):2141\u20132149. https:\/\/doi.org\/10.1002\/hep.29631","journal-title":"Hepatology"},{"issue":"9","key":"6816_CR21","doi-asserted-by":"publisher","first-page":"e2230426","DOI":"10.1001\/jamanetworkopen.2022.30426","volume":"5","author":"J Chhatwal","year":"2022","unstructured":"Chhatwal J, Dalgic OO, Chen W et al (2022) Analysis of a simulation model to estimate long-term outcomes in patients with nonalcoholic fatty liver disease. JAMA Netw Open 5(9):e2230426. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.30426","journal-title":"JAMA Netw Open"},{"issue":"5","key":"6816_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","volume":"6","author":"E Ahlqvist","year":"2018","unstructured":"Ahlqvist E, Storm P, Karajamaki A et al (2018) Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 6(5):361\u2013369. https:\/\/doi.org\/10.1016\/S2213-8587(18)30051-2","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"6816_CR23","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S2213-8587(19)30187-1","volume":"7","author":"OP Zaharia","year":"2019","unstructured":"Zaharia OP, Strassburger K, Strom A et al (2019) Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol 7(9):684\u2013694. https:\/\/doi.org\/10.1016\/S2213-8587(19)30187-1","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"6816_CR24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S2213-8587(23)00329-7","volume":"12","author":"M Schon","year":"2024","unstructured":"Schon M, Prystupa K, Mori T et al (2024) Analysis of type 2 diabetes heterogeneity with a tree-like representation: insights from the prospective German Diabetes Study and the LURIC cohort. Lancet Diabetes Endocrinol 12(2):119\u2013131. https:\/\/doi.org\/10.1016\/S2213-8587(23)00329-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"6816_CR25","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1210\/jc.2007-0482","volume":"92","author":"A Kotronen","year":"2007","unstructured":"Kotronen A, Westerbacka J, Bergholm R, Pietilainen KH, Yki-Jarvinen H (2007) Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 92(9):3490\u20133497. https:\/\/doi.org\/10.1210\/jc.2007-0482","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"6816_CR26","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/joim.70071","volume":"299","author":"O Nabi","year":"2026","unstructured":"Nabi O, Spaak J, Bergstrom G et al (2026) Prevalence and risk factors for metabolic dysfunction-associated steatotic liver disease in Sweden: insights from the SCAPIS cohort. J Intern Med 299(4):481\u2013501. https:\/\/doi.org\/10.1111\/joim.70071","journal-title":"J Intern Med"},{"issue":"6","key":"6816_CR27","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1148\/rg.266065004","volume":"26","author":"OW Hamer","year":"2006","unstructured":"Hamer OW, Aguirre DA, Casola G, Lavine JE, Woenckhaus M, Sirlin CB (2006) Fatty liver: imaging patterns and pitfalls. Radiographics 26(6):1637\u20131653. https:\/\/doi.org\/10.1148\/rg.266065004","journal-title":"Radiographics"},{"issue":"3","key":"6816_CR28","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/hep.24452","volume":"54","author":"R Hernaez","year":"2011","unstructured":"Hernaez R, Lazo M, Bonekamp S et al (2011) Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 54(3):1082\u20131090. https:\/\/doi.org\/10.1002\/hep.24452","journal-title":"Hepatology"},{"issue":"1","key":"6816_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41574-021-00584-0","volume":"18","author":"N Tamaki","year":"2022","unstructured":"Tamaki N, Ajmera V, Loomba R (2022) Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. Nat Rev Endocrinol 18(1):55\u201366. https:\/\/doi.org\/10.1038\/s41574-021-00584-0","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"6816_CR30","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","volume":"66","author":"T Karlas","year":"2017","unstructured":"Karlas T, Petroff D, Sasso M et al (2017) Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol 66(5):1022\u20131030. https:\/\/doi.org\/10.1016\/j.jhep.2016.12.022","journal-title":"J Hepatol"},{"issue":"2","key":"6816_CR31","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/hep.27173","volume":"60","author":"P Bedossa","year":"2014","unstructured":"Bedossa P, FLIP Pathology Consortium (2014) Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 60(2):565\u2013575. https:\/\/doi.org\/10.1002\/hep.27173","journal-title":"Hepatology"},{"issue":"5","key":"6816_CR32","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai PS, Singh S, Patel J et al (2017) Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology 65(5):1557\u20131565. https:\/\/doi.org\/10.1002\/hep.29085","journal-title":"Hepatology"},{"issue":"6","key":"6816_CR33","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","volume":"158","author":"RS Taylor","year":"2020","unstructured":"Taylor RS, Taylor RJ, Bayliss S et al (2020) Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology 158(6):1611-1625 e1612. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.043","journal-title":"Gastroenterology"},{"issue":"7","key":"6816_CR34","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","volume":"70","author":"TG Simon","year":"2021","unstructured":"Simon TG, Roelstraete B, Khalili H, Hagstrom H, Ludvigsson JF (2021) Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut 70(7):1375\u20131382. https:\/\/doi.org\/10.1136\/gutjnl-2020-322786","journal-title":"Gut"},{"issue":"4","key":"6816_CR35","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.cgh.2022.04.014","volume":"21","author":"CH Ng","year":"2023","unstructured":"Ng CH, Lim WH, Hui Lim GE et al (2023) Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 21(4):931-939 e935. https:\/\/doi.org\/10.1016\/j.cgh.2022.04.014","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"2","key":"6816_CR36","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s12325-024-03085-4","volume":"42","author":"R Luthra","year":"2025","unstructured":"Luthra R, Sheth A (2025) Understanding MASH: an examination of progression and clinical outcomes by disease severity in the TARGET-NASH database. Adv Ther 42(2):1165\u20131195. https:\/\/doi.org\/10.1007\/s12325-024-03085-4","journal-title":"Adv Ther"},{"issue":"2","key":"6816_CR37","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S2468-1253(25)00260-2","volume":"11","author":"W Li","year":"2026","unstructured":"Li W, Alazawi W, Loomba R (2026) Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis. Lancet Gastroenterol Hepatol 11(2):150\u2013162. https:\/\/doi.org\/10.1016\/S2468-1253(25)00260-2","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"6816_CR38","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1097\/HEP.0000000000001608","volume":"83","author":"MB Bansal","year":"2026","unstructured":"Bansal MB, Patton H, Morgan TR, Carr RM, Dranoff JA, Allen AM (2026) Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. Hepatology 83(5):1326\u20131340. https:\/\/doi.org\/10.1097\/HEP.0000000000001608","journal-title":"Hepatology"},{"issue":"1","key":"6816_CR39","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","volume":"81","author":"VL Chen","year":"2025","unstructured":"Chen VL, Morgan TR, Rotman Y et al (2025) Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance. Hepatology 81(1):312\u2013320. https:\/\/doi.org\/10.1097\/HEP.0000000000001112","journal-title":"Hepatology"},{"issue":"8","key":"6816_CR40","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1111\/apt.70516","volume":"63","author":"V Ajmera","year":"2026","unstructured":"Ajmera V, Vuppalanchi R, Khalili M et al (2026) Clinical trial: semaglutide versus placebo in NIT-assessed MASH-A multicenter randomised placebo-controlled trial (SAMARA). Aliment Pharmacol Ther 63(8):1080\u20131088. https:\/\/doi.org\/10.1111\/apt.70516","journal-title":"Aliment Pharmacol Ther"},{"key":"6816_CR41","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001734","author":"AJ Sanyal","year":"2026","unstructured":"Sanyal AJ, Abdelmalek MF, Loomba R (2026) Noninvasive surrogate endpoints of adverse outcomes, disease progression, and treatment efficacy in Metabolic Dysfunction-Associated Steatohepatitis (MASH). Hepatology. https:\/\/doi.org\/10.1097\/HEP.0000000000001734","journal-title":"Hepatology"},{"issue":"7","key":"6816_CR42","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","volume":"128","author":"V Ratziu","year":"2005","unstructured":"Ratziu V, Charlotte F, Heurtier A et al (2005) Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128(7):1898\u20131906. https:\/\/doi.org\/10.1053\/j.gastro.2005.03.084","journal-title":"Gastroenterology"},{"issue":"6","key":"6816_CR43","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.jhep.2020.06.025","volume":"73","author":"BA Davison","year":"2020","unstructured":"Davison BA, Harrison SA, Cotter G et al (2020) Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J Hepatol 73(6):1322\u20131332. https:\/\/doi.org\/10.1016\/j.jhep.2020.06.025","journal-title":"J Hepatol"},{"issue":"5","key":"6816_CR44","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.jhep.2024.06.008","volume":"81","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Dubourg J (2024) Liver biopsy evaluation in MASH drug development: think thrice, act wise. J Hepatol 81(5):886\u2013894. https:\/\/doi.org\/10.1016\/j.jhep.2024.06.008","journal-title":"J Hepatol"},{"issue":"4","key":"6816_CR45","doi-asserted-by":"publisher","first-page":"101737","DOI":"10.1016\/j.jhepr.2026.101737","volume":"8","author":"DG Tiniakos","year":"2026","unstructured":"Tiniakos DG, Bedossa P, Arola J et al (2026) The Elucidating Pathways of Steatohepatitis (EPoS) staging system: a reproducible 7-tiered fibrosis scoring system in MASLD. JHEP Rep 8(4):101737. https:\/\/doi.org\/10.1016\/j.jhepr.2026.101737","journal-title":"JHEP Rep"},{"issue":"42","key":"6816_CR46","doi-asserted-by":"publisher","first-page":"5286","DOI":"10.3748\/wjg.v16.i42.5286","volume":"16","author":"EM Brunt","year":"2010","unstructured":"Brunt EM, Tiniakos DG (2010) Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 16(42):5286\u20135296. https:\/\/doi.org\/10.3748\/wjg.v16.i42.5286","journal-title":"World J Gastroenterol"},{"issue":"5","key":"6816_CR47","doi-asserted-by":"publisher","first-page":"e2008","DOI":"10.1210\/clinem\/dgab933","volume":"107","author":"S Qadri","year":"2022","unstructured":"Qadri S, Ahlholm N, Lonsmann I et al (2022) Obesity modifies the performance of fibrosis biomarkers in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 107(5):e2008\u2013e2020. https:\/\/doi.org\/10.1210\/clinem\/dgab933","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"6816_CR48","doi-asserted-by":"publisher","first-page":"290","DOI":"10.2337\/dc19-1071","volume":"43","author":"F Bril","year":"2020","unstructured":"Bril F, McPhaul MJ, Caulfield MP et al (2020) Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes. Diabetes Care 43(2):290\u2013297. https:\/\/doi.org\/10.2337\/dc19-1071","journal-title":"Diabetes Care"},{"key":"6816_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-026-06799-y","author":"M Jonusheit","year":"2026","unstructured":"Jonuscheit M, Schrauwen-Hinderling VB (2026) Imaging of MASLD: clinical standards and novel methods. Diabetologia. https:\/\/doi.org\/10.1007\/s00125-026-06799-y","journal-title":"Diabetologia"},{"issue":"5","key":"6816_CR50","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/ajg.2016.453","volume":"112","author":"S McPherson","year":"2017","unstructured":"McPherson S, Hardy T, Dufour JF et al (2017) Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol 112(5):740\u2013751. https:\/\/doi.org\/10.1038\/ajg.2016.453","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"6816_CR51","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1002\/hep.22109","volume":"47","author":"WR Kim","year":"2008","unstructured":"Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC, Public Policy Committee of the American Association for the Study of Liver D (2008) Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 47(4):1363\u20131370. https:\/\/doi.org\/10.1002\/hep.22109","journal-title":"Hepatology"},{"issue":"6","key":"6816_CR52","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.jhep.2008.03.009","volume":"48","author":"N Afdhal","year":"2008","unstructured":"Afdhal N, McHutchison J, Brown R et al (2008) Thrombocytopenia associated with chronic liver disease. J Hepatol 48(6):1000\u20131007. https:\/\/doi.org\/10.1016\/j.jhep.2008.03.009","journal-title":"J Hepatol"},{"issue":"1","key":"6816_CR53","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/HEP.0000000000000351","volume":"78","author":"G Pennisi","year":"2023","unstructured":"Pennisi G, Enea M, Falco V et al (2023) Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes. Hepatology 78(1):195\u2013211. https:\/\/doi.org\/10.1097\/HEP.0000000000000351","journal-title":"Hepatology"},{"issue":"2","key":"6816_CR54","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","volume":"73","author":"Y Vali","year":"2020","unstructured":"Vali Y, Lee J, Boursier J et al (2020) Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis. J Hepatol 73(2):252\u2013262. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.036","journal-title":"J Hepatol"},{"issue":"5","key":"6816_CR55","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","volume":"71","author":"FE Mozes","year":"2022","unstructured":"Mozes FE, Lee JA, Selvaraj EA et al (2022) Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut 71(5):1006\u20131019. https:\/\/doi.org\/10.1136\/gutjnl-2021-324243","journal-title":"Gut"},{"issue":"3","key":"6816_CR56","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jhep.2023.04.025","volume":"79","author":"JX Liang","year":"2023","unstructured":"Liang JX, Ampuero J, Niu H et al (2023) An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography. J Hepatol 79(3):592\u2013604. https:\/\/doi.org\/10.1016\/j.jhep.2023.04.025","journal-title":"J Hepatol"},{"issue":"3","key":"6816_CR57","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"European Association for the Study of the Liver","year":"2021","unstructured":"European Association for the Study of the Liver (2021) EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 75(3):659\u2013689. https:\/\/doi.org\/10.1016\/j.jhep.2021.05.025","journal-title":"J Hepatol"},{"issue":"12","key":"6816_CR58","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1136\/gutjnl-2023-330269","volume":"72","author":"X Zhang","year":"2023","unstructured":"Zhang X, Yip TC, Wong GL et al (2023) Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial. Gut 72(12):2364\u20132371. https:\/\/doi.org\/10.1136\/gutjnl-2023-330269","journal-title":"Gut"},{"issue":"2","key":"6816_CR59","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/liv.14669","volume":"41","author":"J Lee","year":"2021","unstructured":"Lee J, Vali Y, Boursier J et al (2021) Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review. Liver Int 41(2):261\u2013270. https:\/\/doi.org\/10.1111\/liv.14669","journal-title":"Liver Int"},{"issue":"8","key":"6816_CR60","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S2468-1253(23)00141-3","volume":"8","author":"FE Mozes","year":"2023","unstructured":"Mozes FE, Lee JA, Vali Y et al (2023) Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. Lancet Gastroenterol Hepatol 8(8):704\u2013713. https:\/\/doi.org\/10.1016\/S2468-1253(23)00141-3","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"6816_CR61","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jhep.2021.12.031","volume":"76","author":"J Boursier","year":"2022","unstructured":"Boursier J, Hagstrom H, Ekstedt M et al (2022) Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. J Hepatol 76(5):1013\u20131020. https:\/\/doi.org\/10.1016\/j.jhep.2021.12.031","journal-title":"J Hepatol"},{"issue":"5","key":"6816_CR62","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.cgh.2022.02.059","volume":"21","author":"J Boursier","year":"2023","unstructured":"Boursier J, Canivet CM, Costentin C et al (2023) Impact of type 2 diabetes on the accuracy of noninvasive tests of liver fibrosis with resulting clinical implications. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 21(5):1243-1251 e1212. https:\/\/doi.org\/10.1016\/j.cgh.2022.02.059","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"6816_CR63","doi-asserted-by":"publisher","unstructured":"Younossi ZM, de Avila L, Petta S et al (2026) Diagnostic accuracy of noninvasive tests for metabolic dysfunction-associated steatotic liver disease across age, type 2 diabetes, and obesity subgroups: a multinational study. Clin Gastroenterol Hepatol\u00a0S1542\u20133565(26)00044\u20133. https:\/\/doi.org\/10.1016\/j.cgh.2026.01.016","DOI":"10.1016\/j.cgh.2026.01.016"},{"issue":"2","key":"6816_CR64","doi-asserted-by":"publisher","first-page":"e16240","DOI":"10.1111\/liv.16240","volume":"45","author":"Y Vali","year":"2025","unstructured":"Vali Y, van Dijk AM, Lee J et al (2025) Precision in liver diagnosis: varied accuracy across subgroups and the need for variable thresholds in diagnosis of MASLD. Liver Int 45(2):e16240. https:\/\/doi.org\/10.1111\/liv.16240","journal-title":"Liver Int"},{"issue":"8","key":"6816_CR65","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S2468-1253(23)00017-1","volume":"8","author":"Y Vali","year":"2023","unstructured":"Vali Y, Lee J, Boursier J et al (2023) Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. Lancet Gastroenterol Hepatol 8(8):714\u2013725. https:\/\/doi.org\/10.1016\/S2468-1253(23)00017-1","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"6816_CR66","doi-asserted-by":"publisher","unstructured":"Arai T, Takahashi H, Seko Y et al (2024) Accuracy of the enhanced liver fibrosis test in patients with type 2 diabetes mellitus and its clinical implications. Clin Gastroenterol Hepatol 22(4):789\u2013797.e788. https:\/\/doi.org\/10.1016\/j.cgh.2023.11.022","DOI":"10.1016\/j.cgh.2023.11.022"},{"issue":"9","key":"6816_CR67","doi-asserted-by":"publisher","first-page":"e2123923","DOI":"10.1001\/jamanetworkopen.2021.23923","volume":"4","author":"ZM Younossi","year":"2021","unstructured":"Younossi ZM, Felix S, Jeffers T et al (2021) Performance of the enhanced liver fibrosis test to estimate advanced fibrosis among patients with nonalcoholic fatty liver disease. JAMA Netw Open 4(9):e2123923. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.23923","journal-title":"JAMA Netw Open"},{"key":"6816_CR68","doi-asserted-by":"publisher","unstructured":"Are VS, Vuppalanchi R, Vilar-Gomez E, Chalasani N (2021) Enhanced liver fibrosis score can be used to predict liver-related events in patients with nonalcoholic steatohepatitis and compensated cirrhosis. Clin Gastroenterol Hepatol 19(6):1292\u20131293.e1293. https:\/\/doi.org\/10.1016\/j.cgh.2020.06.070","DOI":"10.1016\/j.cgh.2020.06.070"},{"issue":"5","key":"6816_CR69","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1373\/jalm.2018.027359","volume":"3","author":"J Day","year":"2019","unstructured":"Day J, Patel P, Parkes J, Rosenberg W (2019) Derivation and performance of standardized Enhanced Liver Fibrosis (ELF) test thresholds for the detection and prognosis of liver fibrosis. J Appl Lab Med 3(5):815\u2013826. https:\/\/doi.org\/10.1373\/jalm.2018.027359","journal-title":"J Appl Lab Med"},{"issue":"12","key":"6816_CR70","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1038\/ajg.2012.331","volume":"107","author":"VW Wong","year":"2012","unstructured":"Wong VW, Vergniol J, Wong GL et al (2012) Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 107(12):1862\u20131871. https:\/\/doi.org\/10.1038\/ajg.2012.331","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"6816_CR71","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1053\/j.gastro.2008.09.013","volume":"136","author":"V Nobili","year":"2009","unstructured":"Nobili V, Parkes J, Bottazzo G et al (2009) Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology 136(1):160\u2013167. https:\/\/doi.org\/10.1053\/j.gastro.2008.09.013","journal-title":"Gastroenterology"},{"issue":"5","key":"6816_CR72","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.jhep.2024.11.049","volume":"82","author":"P Cales","year":"2025","unstructured":"Cales P, Canivet CM, Costentin C et al (2025) A new generation of non-invasive tests of liver fibrosis with improved accuracy in MASLD. J Hepatol 82(5):794\u2013804. https:\/\/doi.org\/10.1016\/j.jhep.2024.11.049","journal-title":"J Hepatol"},{"issue":"10","key":"6816_CR73","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1038\/s41591-023-02539-6","volume":"29","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal AJ, Shankar SS, Yates KP et al (2023) Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis. Nat Med 29(10):2656\u20132664. https:\/\/doi.org\/10.1038\/s41591-023-02539-6","journal-title":"Nat Med"},{"issue":"2","key":"6816_CR74","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jhep.2024.03.023","volume":"81","author":"L Castera","year":"2024","unstructured":"Castera L, Garteiser P, Laouenan C et al (2024) Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes. J Hepatol 81(2):195\u2013206. https:\/\/doi.org\/10.1016\/j.jhep.2024.03.023","journal-title":"J Hepatol"},{"key":"6816_CR75","doi-asserted-by":"publisher","unstructured":"Tavaglione F, Jamialahmadi O, De Vincentis A et al (2022) Development and validation of a score for fibrotic nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 21(6):1523\u201315032.e1.\u00a0https:\/\/doi.org\/10.1016\/j.cgh.2022.03.044","DOI":"10.1016\/j.cgh.2022.03.044"},{"issue":"11","key":"6816_CR76","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1111\/liv.15406","volume":"42","author":"A Pina","year":"2022","unstructured":"Pina A, Meneses MJ, Ribeiro RT, Raposo JF, Macedo MP (2022) Fibrosis nonalcoholic steatohepatitis index validation and applicability considering glycaemic severity and T2D duration. Liver Int 42(11):2577\u20132580. https:\/\/doi.org\/10.1111\/liv.15406","journal-title":"Liver Int"},{"key":"6816_CR77","doi-asserted-by":"publisher","unstructured":"Canivet CM, Zheng MH, Qadri S et al (2023) Validation of the blood test MACK-3 for the noninvasive diagnosis of fibrotic nonalcoholic steatohepatitis: an international study with 1924 patients. Clin Gastroenterol Hepatol 21(12):3097\u20133106.e3010. https:\/\/doi.org\/10.1016\/j.cgh.2023.03.032","DOI":"10.1016\/j.cgh.2023.03.032"},{"issue":"11","key":"6816_CR78","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","volume":"5","author":"SA Harrison","year":"2020","unstructured":"Harrison SA, Ratziu V, Boursier J et al (2020) A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol 5(11):970\u2013985. https:\/\/doi.org\/10.1016\/S2468-1253(20)30252-1","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"6816_CR79","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1136\/gutjnl-2018-317334","volume":"68","author":"VW Wong","year":"2019","unstructured":"Wong VW, Irles M, Wong GL et al (2019) Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. Gut 68(11):2057\u20132064. https:\/\/doi.org\/10.1136\/gutjnl-2018-317334","journal-title":"Gut"},{"issue":"15","key":"6816_CR80","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jama.2024.1447","volume":"331","author":"H Lin","year":"2024","unstructured":"Lin H, Lee HW, Yip TC et al (2024) Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease. JAMA 331(15):1287\u20131297. https:\/\/doi.org\/10.1001\/jama.2024.1447","journal-title":"JAMA"},{"issue":"7","key":"6816_CR81","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1111\/liv.15919","volume":"44","author":"H Hegmar","year":"2024","unstructured":"Hegmar H, Wester A, Aleman S et al (2024) Liver stiffness predicts progression to liver-related events in patients with chronic liver disease - A cohort study of 14 414 patients. Liver Int 44(7):1689\u20131699. https:\/\/doi.org\/10.1111\/liv.15919","journal-title":"Liver Int"},{"issue":"3","key":"6816_CR82","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1136\/gutjnl-2022-327777","volume":"72","author":"R Loomba","year":"2023","unstructured":"Loomba R, Huang DQ, Sanyal AJ et al (2023) Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. Gut 72(3):581\u2013589. https:\/\/doi.org\/10.1136\/gutjnl-2022-327777","journal-title":"Gut"},{"issue":"7","key":"6816_CR83","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1007\/s10620-025-08850-1","volume":"70","author":"E Truong","year":"2025","unstructured":"Truong E, Alnimer L, Gornbein JA et al (2025) Agile 3+ and 4 scores accurately predict major adverse liver outcomes, liver transplant, progression of MELD score, the development of hepatocellular carcinoma, and death in NAFLD. Dig Dis Sci 70(7):2487\u20132495. https:\/\/doi.org\/10.1007\/s10620-025-08850-1","journal-title":"Dig Dis Sci"},{"issue":"4","key":"6816_CR84","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jhep.2011.10.017","volume":"56","author":"V de Ledinghen","year":"2012","unstructured":"de Ledinghen V, Wong VW, Vergniol J et al (2012) Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan(R). J Hepatol 56(4):833\u2013839. https:\/\/doi.org\/10.1016\/j.jhep.2011.10.017","journal-title":"J Hepatol"},{"issue":"3","key":"6816_CR85","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/hep.23425","volume":"51","author":"L Castera","year":"2010","unstructured":"Castera L, Foucher J, Bernard PH et al (2010) Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 51(3):828\u2013835. https:\/\/doi.org\/10.1002\/hep.23425","journal-title":"Hepatology"},{"issue":"4","key":"6816_CR86","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jhep.2006.11.010","volume":"46","author":"A Kettaneh","year":"2007","unstructured":"Kettaneh A, Marcellin P, Douvin C et al (2007) Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J Hepatol 46(4):628\u2013634. https:\/\/doi.org\/10.1016\/j.jhep.2006.11.010","journal-title":"J Hepatol"},{"issue":"9","key":"6816_CR87","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1007\/s00261-022-03597-z","volume":"47","author":"RL Ehman","year":"2022","unstructured":"Ehman RL (2022) Magnetic resonance elastography: from invention to standard of care. Abdom Radiol (NY) 47(9):3028\u20133036. https:\/\/doi.org\/10.1007\/s00261-022-03597-z","journal-title":"Abdom Radiol (NY)"},{"issue":"2","key":"6816_CR88","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jhep.2022.10.034","volume":"78","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal AJ, Foucquier J, Younossi ZM et al (2023) Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores. J Hepatol 78(2):247\u2013259. https:\/\/doi.org\/10.1016\/j.jhep.2022.10.034","journal-title":"J Hepatol"},{"issue":"8","key":"6816_CR89","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1111\/liv.15914","volume":"44","author":"FE Mozes","year":"2024","unstructured":"Mozes FE, Lee JA, Vali Y et al (2024) Diagnostic accuracy of non-invasive tests to screen for at-risk MASH-An individual participant data meta-analysis. Liver Int 44(8):1872\u20131885. https:\/\/doi.org\/10.1111\/liv.15914","journal-title":"Liver Int"},{"issue":"7","key":"6816_CR90","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2337\/dci24-0094","volume":"48","author":"K Cusi","year":"2025","unstructured":"Cusi K, Abdelmalek MF, Apovian CM et al (2025) Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association. Diabetes Care 48(7):1057\u20131082. https:\/\/doi.org\/10.2337\/dci24-0094","journal-title":"Diabetes Care"},{"issue":"1","key":"6816_CR91","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE et al (2018) The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67(1):328\u2013357. https:\/\/doi.org\/10.1002\/hep.29367","journal-title":"Hepatology"},{"issue":"2","key":"6816_CR92","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1053\/j.gastro.2023.04.025","volume":"165","author":"DQ Huang","year":"2023","unstructured":"Huang DQ, Wilson LA, Behling C et al (2023) Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study. Gastroenterology 165(2):463\u2013472. https:\/\/doi.org\/10.1053\/j.gastro.2023.04.025","journal-title":"Gastroenterology"},{"issue":"13","key":"6816_CR93","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/j.cgh.2019.04.038","volume":"17","author":"K Bjorkstrom","year":"2019","unstructured":"Bjorkstrom K, Franzen S, Eliasson B et al (2019) Risk factors for severe liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 17(13):2769-2775 e2764. https:\/\/doi.org\/10.1016\/j.cgh.2019.04.038","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"3","key":"6816_CR94","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/hep.31014","volume":"71","author":"F Kanwal","year":"2020","unstructured":"Kanwal F, Kramer JR, Li L et al (2020) Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease. Hepatology 71(3):808\u2013819. https:\/\/doi.org\/10.1002\/hep.31014","journal-title":"Hepatology"},{"issue":"6","key":"6816_CR95","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00125-024-06087-7","volume":"67","author":"S Qadri","year":"2024","unstructured":"Qadri S, Yki-Jarvinen H (2024) Surveillance of the liver in type 2 diabetes: important but unfeasible? Diabetologia 67(6):961\u2013973. https:\/\/doi.org\/10.1007\/s00125-024-06087-7","journal-title":"Diabetologia"},{"issue":"1","key":"6816_CR96","doi-asserted-by":"publisher","first-page":"52","DOI":"10.15605\/jafes.038.01.08","volume":"38","author":"XH Lee","year":"2023","unstructured":"Lee XH, Nor LM, Ang CS, Yeow TP, Lim SL (2023) The prevalence of advanced liver fibrosis among patients with type 2 diabetes mellitus: a single-centre experience in Penang, Malaysia. J ASEAN Fed Endocr Soc 38(1):52\u201361. https:\/\/doi.org\/10.15605\/jafes.038.01.08","journal-title":"J ASEAN Fed Endocr Soc"},{"issue":"8","key":"6816_CR97","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1111\/jgh.14577","volume":"34","author":"LL Lai","year":"2019","unstructured":"Lai LL, Wan Yusoff WNI, Vethakkan SR, Nik Mustapha NR, Mahadeva S, Chan WK (2019) Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography. J Gastroenterol Hepatol 34(8):1396\u20131403. https:\/\/doi.org\/10.1111\/jgh.14577","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"6816_CR98","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3390\/jcm9041032","volume":"9","author":"I Sporea","year":"2020","unstructured":"Sporea I, Mare R, Popescu A et al (2020) Screening for liver fibrosis and steatosis in a large cohort of patients with type 2 diabetes using vibration controlled transient elastography and controlled attenuation parameter in a single-center real-life experience. J Clin Med 9(4):1032. https:\/\/doi.org\/10.3390\/jcm9041032","journal-title":"J Clin Med"},{"issue":"8","key":"6816_CR99","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1136\/gutjnl-2015-309265","volume":"65","author":"R Kwok","year":"2016","unstructured":"Kwok R, Choi KC, Wong GL et al (2016) Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut 65(8):1359\u20131368. https:\/\/doi.org\/10.1136\/gutjnl-2015-309265","journal-title":"Gut"},{"issue":"2","key":"6816_CR100","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2337\/dc20-1778","volume":"44","author":"S Ciardullo","year":"2021","unstructured":"Ciardullo S, Monti T, Perseghin G (2021) High prevalence of advanced liver fibrosis assessed by transient elastography among U.S. adults with type 2 diabetes. Diabetes Care 44(2):519\u2013525. https:\/\/doi.org\/10.2337\/dc20-1778","journal-title":"Diabetes Care"},{"key":"6816_CR101","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejim.2020.08.005","volume":"82","author":"I Mikolasevic","year":"2020","unstructured":"Mikolasevic I, Domislovic V, Turk Wensveen T et al (2020) Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study. Eur J Intern Med 82:68\u201375. https:\/\/doi.org\/10.1016\/j.ejim.2020.08.005","journal-title":"Eur J Intern Med"},{"issue":"8","key":"6816_CR102","doi-asserted-by":"publisher","first-page":"e0236977","DOI":"10.1371\/journal.pone.0236977","volume":"15","author":"K Chen","year":"2020","unstructured":"Chen K, Sng WK, Quah JH et al (2020) Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus. PLoS One 15(8):e0236977. https:\/\/doi.org\/10.1371\/journal.pone.0236977","journal-title":"PLoS One"},{"issue":"2","key":"6816_CR103","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2337\/dc20-1997","volume":"44","author":"R Lomonaco","year":"2021","unstructured":"Lomonaco R, Godinez Leiva E, Bril F et al (2021) Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening. Diabetes Care 44(2):399\u2013406. https:\/\/doi.org\/10.2337\/dc20-1997","journal-title":"Diabetes Care"},{"issue":"3","key":"6816_CR104","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/apt.15626","volume":"51","author":"KA Kang","year":"2020","unstructured":"Kang KA, Jun DW, Kim MS, Kwon HJ, Nguyen MH (2020) Prevalence of significant hepatic fibrosis using magnetic resonance elastography in a health check-up clinic population. Aliment Pharmacol Ther 51(3):388\u2013396. https:\/\/doi.org\/10.1111\/apt.15626","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"6816_CR105","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00038-012-0439-9","volume":"58","author":"N Speybroeck","year":"2013","unstructured":"Speybroeck N, Devleesschauwer B, Joseph L, Berkvens D (2013) Misclassification errors in prevalence estimation: Bayesian handling with care. Int J Public Health 58(5):791\u2013795. https:\/\/doi.org\/10.1007\/s00038-012-0439-9","journal-title":"Int J Public Health"},{"issue":"6","key":"6816_CR106","doi-asserted-by":"publisher","first-page":"E101","DOI":"10.1097\/HEP.0000000000000464","volume":"78","author":"F Aberg","year":"2023","unstructured":"Aberg F (2023) Letter to the Editor: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate? Hepatology 78(6):E101\u2013E102. https:\/\/doi.org\/10.1097\/HEP.0000000000000464","journal-title":"Hepatology"},{"key":"6816_CR107","doi-asserted-by":"publisher","unstructured":"Jackson BR (2008) The dangers of false-positive and false-negative test results: false-positive results as a function of pretest probability. Clin Lab Med 28(2): 305\u2013319, vii. https:\/\/doi.org\/10.1016\/j.cll.2007.12.009","DOI":"10.1016\/j.cll.2007.12.009"},{"issue":"7","key":"6816_CR108","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.2337\/dc22-2048","volume":"46","author":"L Castera","year":"2023","unstructured":"Castera L, Laouenan C, Vallet-Pichard A et al (2023) High prevalence of NASH and advanced fibrosis in type 2 diabetes: a prospective study of 330 outpatients undergoing liver biopsies for elevated ALT, using a low threshold. Diabetes Care 46(7):1354\u20131362. https:\/\/doi.org\/10.2337\/dc22-2048","journal-title":"Diabetes Care"},{"issue":"1","key":"6816_CR109","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/oxfordjournals.aje.a112510","volume":"107","author":"WJ Rogan","year":"1978","unstructured":"Rogan WJ, Gladen B (1978) Estimating prevalence from the results of a screening test. Am J Epidemiol 107(1):71\u201376. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a112510","journal-title":"Am J Epidemiol"},{"key":"6816_CR110","doi-asserted-by":"publisher","unstructured":"Singh S, Venkatesh SK, Wang Z et al (2015) Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol 13(3):440\u2013451.e446. https:\/\/doi.org\/10.1016\/j.cgh.2014.09.046","DOI":"10.1016\/j.cgh.2014.09.046"},{"key":"6816_CR111","doi-asserted-by":"publisher","unstructured":"Hsu C, Caussy C, Imajo K et al (2019) Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol 17(4):630\u2013637.e638. https:\/\/doi.org\/10.1016\/j.cgh.2018.05.059","DOI":"10.1016\/j.cgh.2018.05.059"},{"key":"6816_CR112","doi-asserted-by":"publisher","first-page":"i3139","DOI":"10.1136\/bmj.i3139","volume":"353","author":"JA Usher-Smith","year":"2016","unstructured":"Usher-Smith JA, Sharp SJ, Griffin SJ (2016) The spectrum effect in tests for risk prediction, screening, and diagnosis. BMJ 353:i3139. https:\/\/doi.org\/10.1136\/bmj.i3139","journal-title":"BMJ"},{"key":"6816_CR113","doi-asserted-by":"crossref","unstructured":"Zhou XH, Obuchowski NA, McClish DK (2011) Measures of diagnostic accuracy. In: Statistical methods in diagnostic medicine. Wiley, Hoboken, NJ, USA, pp 13\u201355","DOI":"10.1002\/9780470906514.ch2"},{"issue":"1","key":"6816_CR114","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s41512-024-00175-3","volume":"8","author":"TR Fanshawe","year":"2024","unstructured":"Fanshawe TR, Nicholson BD, Perera R, Oke JL (2024) A review of methods for the analysis of diagnostic tests performed in sequence. Diagn Progn Res 8(1):8. https:\/\/doi.org\/10.1186\/s41512-024-00175-3","journal-title":"Diagn Progn Res"},{"issue":"6","key":"6816_CR115","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2337\/dc24-2075","volume":"48","author":"C Caussy","year":"2025","unstructured":"Caussy C, Verges B, Leleu D et al (2025) Screening for metabolic dysfunction-associated steatotic liver disease-related advanced fibrosis in diabetology: a prospective multicenter study. Diabetes Care 48(6):877\u2013886. https:\/\/doi.org\/10.2337\/dc24-2075","journal-title":"Diabetes Care"},{"issue":"1","key":"6816_CR116","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/dom.70245","volume":"28","author":"A Mantovani","year":"2026","unstructured":"Mantovani A, Lombardi R, Dalbeni A et al (2026) Two-tier screening approach for liver fibrosis stratification in outpatients with type 2 diabetes mellitus: a multicenter cross-sectional study. Diabetes Obes Metab 28(1):644\u2013653. https:\/\/doi.org\/10.1111\/dom.70245","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"6816_CR117","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1016\/j.cgh.2025.02.018","volume":"23","author":"T Vidal-Trecan","year":"2025","unstructured":"Vidal-Trecan T, Julla JB, El Khoury T et al (2025) Effectiveness of six international guidelines using fibrosis-4 and FibroScan for risk stratification of metabolic dysfunction-associated steatotic liver disease in type 2 diabetes. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 23(12):2176-2186 e2172. https:\/\/doi.org\/10.1016\/j.cgh.2025.02.018","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"2","key":"6816_CR118","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1016\/j.jhep.2025.02.018","volume":"83","author":"M Roeren","year":"2025","unstructured":"Roeren M, Grip ET, Skroder H, Shang Y, Hagstrom H (2025) Potential issues with implementation of EASL-EASD-EASO guidelines on management of MASLD in patients with type 2 diabetes in Sweden. J Hepatol 83(2):e95\u2013e97. https:\/\/doi.org\/10.1016\/j.jhep.2025.02.018","journal-title":"J Hepatol"},{"issue":"2","key":"6816_CR119","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S2468-1253(24)00313-3","volume":"10","author":"A Lindfors","year":"2025","unstructured":"Lindfors A, Strandberg R, Hagstrom H (2025) Screening for advanced liver fibrosis due to metabolic dysfunction-associated steatotic liver disease alongside retina scanning in people with type 2 diabetes: a cross-sectional study. Lancet Gastroenterol Hepatol 10(2):125\u2013137. https:\/\/doi.org\/10.1016\/S2468-1253(24)00313-3","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10537","key":"6816_CR120","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/S0140-6736(26)00354-5","volume":"407","author":"I Graupera","year":"2026","unstructured":"Graupera I, Thiele M, Castera L et al (2026) Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort study. Lancet 407(10537):1448\u20131458. https:\/\/doi.org\/10.1016\/S0140-6736(26)00354-5","journal-title":"Lancet"},{"key":"6816_CR121","volume-title":"Principles and practice of screening for disease","author":"JMG Wilson","year":"1968","unstructured":"Wilson JMG, Jungner G (1968) Principles and practice of screening for disease. WHO, Geneva, Switzerland"},{"key":"6816_CR122","unstructured":"Sagan A, McDaid D, Rajan S, Farrington J, McKee M (2020) Screening: when is it appropriate and how can we get it right? Policy Brief no. 35. European Observatory on Health Systems and Policies, Copenhagen, Denmark"},{"issue":"11","key":"6816_CR123","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1136\/gutjnl-2023-331331","volume":"73","author":"Y Shang","year":"2024","unstructured":"Shang Y, Akbari C, Dodd M et al (2024) Cause of death by fibrosis stage in 959 patients with biopsy-proven NAFLD. Gut 73(11):e30. https:\/\/doi.org\/10.1136\/gutjnl-2023-331331","journal-title":"Gut"},{"issue":"5","key":"6816_CR124","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1097\/HEP.0000000000001015","volume":"81","author":"DQ Huang","year":"2025","unstructured":"Huang DQ, Wilson LA, Behling C et al (2025) Liver stiffness progression in biopsy-proven metabolic dysfunction-associated steatotic disease among people with diabetes versus people without diabetes: a prospective multicenter study. Hepatology 81(5):1553\u20131563. https:\/\/doi.org\/10.1097\/HEP.0000000000001015","journal-title":"Hepatology"},{"issue":"9","key":"6816_CR125","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2468-1253(23)00157-7","volume":"8","author":"DQ Huang","year":"2023","unstructured":"Huang DQ, Noureddin N, Ajmera V et al (2023) Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis. Lancet Gastroenterol Hepatol 8(9):829\u2013836. https:\/\/doi.org\/10.1016\/S2468-1253(23)00157-7","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"6816_CR126","doi-asserted-by":"publisher","first-page":"978","DOI":"10.2337\/dc23-1937","volume":"47","author":"Y Shang","year":"2024","unstructured":"Shang Y, Grip ET, Modica A et al (2024) Metabolic syndrome traits increase the risk of major adverse liver outcomes in type 2 diabetes. Diabetes Care 47(6):978\u2013985. https:\/\/doi.org\/10.2337\/dc23-1937","journal-title":"Diabetes Care"},{"issue":"1","key":"6816_CR127","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00125-005-0063-9","volume":"49","author":"RN Guzder","year":"2006","unstructured":"Guzder RN, Gatling W, Mullee MA, Byrne CD (2006) Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. Diabetologia 49(1):49\u201355. https:\/\/doi.org\/10.1007\/s00125-005-0063-9","journal-title":"Diabetologia"},{"key":"6816_CR128","unstructured":"World Health Organization (2020) Screening programmes: a short guide. Increase effectiveness, maximize benefits and minimize harm. WHO Regional Office for Europe, Copenhagen, Denmark"},{"issue":"4","key":"6816_CR129","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S2213-8587(19)30411-5","volume":"8","author":"S Vujosevic","year":"2020","unstructured":"Vujosevic S, Aldington SJ, Silva P et al (2020) Screening for diabetic retinopathy: new perspectives and challenges. Lancet Diabetes Endocrinol 8(4):337\u2013347. https:\/\/doi.org\/10.1016\/S2213-8587(19)30411-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"15","key":"6816_CR130","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1001\/jama.2015.13183","volume":"314","author":"ER Myers","year":"2015","unstructured":"Myers ER, Moorman P, Gierisch JM et al (2015) Benefits and harms of breast cancer screening: a systematic review. JAMA 314(15):1615\u20131634. https:\/\/doi.org\/10.1001\/jama.2015.13183","journal-title":"JAMA"},{"key":"6816_CR131","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/2046-4053-2-35","volume":"2","author":"L Peirson","year":"2013","unstructured":"Peirson L, Fitzpatrick-Lewis D, Ciliska D, Warren R (2013) Screening for cervical cancer: a systematic review and meta-analysis. Syst Rev 2:35. https:\/\/doi.org\/10.1186\/2046-4053-2-35","journal-title":"Syst Rev"},{"issue":"Suppl 1","key":"6816_CR132","doi-asserted-by":"publisher","first-page":"S166","DOI":"10.2337\/dc26-S008","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes (2026) 8. Obesity and weight management for the prevention and treatment of diabetes: standards of care in diabetes-2026. Diabetes Care 49(Suppl 1):S166\u2013S182. https:\/\/doi.org\/10.2337\/dc26-S008","journal-title":"Diabetes Care"},{"key":"6816_CR133","unstructured":"European Medicines Agency (2026) Ozempic (semaglutide): EPAR \u2013 Product Information. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ozempic-epar-product-information_en.pdf. Accessed: 13 May 2026"},{"key":"6816_CR134","unstructured":"European Medicines Agency (2026) Wegovy (semaglutide): EPAR \u2013 Product Information. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/wegovy-epar-product-information_en.pdf. Accessed: 13 May 2026"},{"issue":"2","key":"6816_CR135","doi-asserted-by":"publisher","first-page":"272","DOI":"10.14309\/ajg.0000000000002922","volume":"120","author":"AST Barritt","year":"2025","unstructured":"Barritt AST, Stine JG (2025) Update on newly federal drug administration-approved drug, resmetirom: a practical perspective. Am J Gastroenterol 120(2):272\u2013276. https:\/\/doi.org\/10.14309\/ajg.0000000000002922","journal-title":"Am J Gastroenterol"},{"issue":"18","key":"6816_CR136","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/jama.2023.5997","volume":"329","author":"EB Tapper","year":"2023","unstructured":"Tapper EB, Parikh ND (2023) Diagnosis and management of cirrhosis and its complications: a review. JAMA 329(18):1589\u20131602. https:\/\/doi.org\/10.1001\/jama.2023.5997","journal-title":"JAMA"},{"issue":"5","key":"6816_CR137","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1053\/j.gastro.2020.07.050","volume":"159","author":"M Noureddin","year":"2020","unstructured":"Noureddin M, Jones C, Alkhouri N et al (2020) Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the united states is cost-effective: a comprehensive cost-utility analysis. Gastroenterology 159(5):1985-1987 e1984. https:\/\/doi.org\/10.1053\/j.gastro.2020.07.050","journal-title":"Gastroenterology"},{"issue":"5","key":"6816_CR138","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"K Cusi","year":"2022","unstructured":"Cusi K, Isaacs S, Barb D et al (2022) American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract 28(5):528\u2013562. https:\/\/doi.org\/10.1016\/j.eprac.2022.03.010","journal-title":"Endocr Pract"},{"issue":"4","key":"6816_CR139","doi-asserted-by":"publisher","first-page":"e16119","DOI":"10.1111\/liv.16119","volume":"45","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Paik JM, Henry L, Stepanova M, Nader F (2025) Pharmaco-economic assessment of screening strategies for high-risk MASLD in primary care. Liver Int 45(4):e16119. https:\/\/doi.org\/10.1111\/liv.16119","journal-title":"Liver Int"},{"issue":"2","key":"6816_CR140","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S2213-8587(25)00299-2","volume":"14","author":"I Genitsaridi","year":"2026","unstructured":"Genitsaridi I, Salpea P, Salim A et al (2026) 11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050. Lancet Diabetes Endocrinol 14(2):149\u2013156. https:\/\/doi.org\/10.1016\/S2213-8587(25)00299-2","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"6816_CR141","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","volume":"2","author":"H Yki-Jarvinen","year":"2014","unstructured":"Yki-Jarvinen H (2014) Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2(11):901\u2013910. https:\/\/doi.org\/10.1016\/S2213-8587(14)70032-4","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06816-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-026-06816-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06816-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:39:27Z","timestamp":1790771967000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-026-06816-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":141,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["6816"],"URL":"https:\/\/doi.org\/10.1007\/s00125-026-06816-0","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Open Access funding provided by University of Helsinki (including Helsinki University Central Hospital). Research in the author\u2019s laboratory is supported by the EFSD and Novo Nordisk A\/S Programme for Diabetes Research in Europe 2025.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The author declares that there are no relationships or activities that might bias, or be perceived to bias, their work.","order":2,"name":"Ethics","label":"Author\u2019s relationships and activities","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"SFQ was the sole author responsible for this work.","order":3,"name":"Ethics","label":"Contribution statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}